Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.68

-0.17 (-0.46%)

, BMY

Bristol-Myers

$56.98

0.23 (0.41%)

07:31
11/28/16
11/28
07:31
11/28/16
07:31

Mylan signs sub-license agreement with Medicines Patent Pool

Mylan (MYL) announced that the company has signed an agreement with the Medicines Patent Pool to expand access to chronic hepatitis C medicines in developing countries. The agreement licenses Mylan to produce and market a generic version of Bristol-Myers Squibb's (BMY) DAKLINZA Tablets, 30 mg and 60 mg, for distribution in 112 low and middle income countries. Daclatasvir Tablets, 30 mg and 60 mg, are indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus genotype 1 or genotype 3 infection in the U.S. and genotype 1, 3 and 4 in Europe. The license allows Mylan to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of HCV. Earlier this year, the World Health Organization added several new hepatitis C treatments, including daclatasvir, to its essential medicines list, highlighting the urgent need to promote equitable access to innovative medicines.

MYL

Mylan

$36.68

-0.17 (-0.46%)

BMY

Bristol-Myers

$56.98

0.23 (0.41%)

  • 03

    Dec

  • 28

    Mar

MYL Mylan
$36.68

-0.17 (-0.46%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/16
MZHO
10/25/16
INITIATION
Target $49
MZHO
Buy
Mylan initiated with a Buy at Mizuho
Mizuho analyst Irina Koffler initiated Mylan with a Buy and a $49 price target.
10/26/16
10/26/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL) initiated with a Buy at Mizuho. 2. Five Below (FIVE) initiated with a Buy at Longbow. 3. NetSuite (N) reinstated with an Underperform at BofA/Merrill. 4. Adient (ADNT) initiated with a Buy at Northcoast. 5. Party City (PRTY) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$56.98

0.23 (0.41%)

10/28/16
HDLY
10/28/16
UPGRADE
HDLY
Long-Term Buy
Bristol-Myers upgraded to Long-Term Buy from Neutral at Hilliard Lyons
10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$918.38

9.09 (1.00%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

LH

LabCorp

$139.68

0.99 (0.71%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Hot Stocks
LabCorp to exclusively offer M3 Checklist for mental illness »

LabCorp and M-3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

ATTO

Atento

$8.85

-0.1 (-1.12%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Earnings
Atento announces prepayment of $27M Brazilian debentures »

Atento made a $26.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide an…

TER

Teradyne

$36.35

2.58 (7.64%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Teradyne analyst commentary  »

Teradyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 21

    Jun

EXPE

Expedia

$136.20

0.45 (0.33%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Expedia analyst commentary  »

Expedia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

LLL

L3 Technologies

$173.94

2.18 (1.27%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
L3 Technologies analyst commentary  »

L3 Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

, SYK

Stryker

$135.37

-0.82 (-0.60%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Downgrade
Zimmer Biomet, Stryker rating change  »

Zimmer Biomet downgraded…

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

SYK

Stryker

$135.37

-0.82 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 04

    May

PTEN

Patterson-UTI

$21.93

-1.07 (-4.65%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Recommendations
Patterson-UTI analyst commentary  »

Patterson-UTI weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

MGA

Magna

$41.40

0.56 (1.37%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Magna enters joint venture with Chinese seating supplier »

Magna has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 11

    May

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Exxon Mobil says Q1 Chemical earnings impacted primarily by lower margins »

Exxon Mobil reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

RWLK

ReWalk Robotics

$1.45

-0.2 (-12.12%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
ReWalk Robotics names Jodi Gricci as Chief Commercial Officer »

ReWalk Robotics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

HON

Honeywell

$129.88

-0.22 (-0.17%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Periodicals
Honeywell talks with Third Point still friendly, CNBC's Faber says »

Talks between Honeywell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FSS

Federal Signal

$15.38

0.98 (6.81%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
Federal Signal awarded $128K of legal costs in hearing loss litigation »

Federal Signal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.10

-0.0099 (-9.00%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Hot Stocks
CEL-SCI says European Patent office to grant new Multikine patent »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$33.05

-0.18 (-0.54%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Technical Analysis
Synchrony drops sharply after earnings miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

  • 31

    May

MSFT

Microsoft

$68.27

0.44 (0.65%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Recommendations
Microsoft analyst commentary  »

Microsoft commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:08
04/28/17
04/28
08:08
04/28/17
08:08
Hot Stocks
Royal Caribbean sees FY17 CapEx $0.6B »

Based upon current ship…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

ACBI

Atlantic Capital

08:07
04/28/17
04/28
08:07
04/28/17
08:07
Earnings
Atlantic Capital reports Q1 EPS 13c, consensus 14c »

Taxable equivalent net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:07
04/28/17
04/28
08:07
04/28/17
08:07
Earnings
Royal Caribbean sees Q2 adjusted EPS $1.60-$1.65, consensus $1.44 »

Constant-Currency Net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:07
04/28/17
04/28
08:07
04/28/17
08:07
Hot Stocks
Exxon Mobil reports Q1 capital and exploration expenditures down 19% »

Capital and exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

MXWL

Maxwell

$6.24

-0.03 (-0.48%)

08:06
04/28/17
04/28
08:06
04/28/17
08:06
Earnings
Maxwell sees Nesscap Energy acquisition immediately accretive to non-GAAP EPS »

Acquisition is expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 13

    Jul

RTN

Raytheon

$156.26

0.99 (0.64%)

08:06
04/28/17
04/28
08:06
04/28/17
08:06
Recommendations
Raytheon analyst commentary  »

Raytheon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:05
04/28/17
04/28
08:05
04/28/17
08:05
Hot Stocks
Breaking Hot Stocks news story on Royal Caribbean »

Royal Caribbean announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CIR

CIRCOR

$65.03

-0.22 (-0.34%)

08:05
04/28/17
04/28
08:05
04/28/17
08:05
Earnings
CIRCOR reports Q1 adjusted EPS 32c, consensus 35c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 10

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.